Canary Wharf, like many urban commercial centres, is changing fast. This small but significant district has long been a centre of commerce, growth and innovation – initially for maritime trade and most recently as a hub for banking and finance.
Now that it is grappling with empty commercial space and falling demand following the pandemic, could it be about to undergo another transformation – into a world-leading epicentre for science?
With high-profile JVs involving Kadans and investment arriving from hVIVO and other innovation specialists, Canary Wharf is, in my view, perfect for the life sciences sector. However, given the technical complexity and fast-moving nature of the science market, developers need to think carefully before piling in.
hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.
